ArticlePharmaceutics2022
Competitiveness during Dual-Species Biofilm Formation of
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Preliminary Evaluation of Gemini-Surfactant-Based Formulations for Antifungal Seed Treatment in Wheat.Molecules (Basel, Switzerland) · 2026Article
- Mating-Type Loci Modulate Pathogenicity and Non-Sexual Development Through Autocrine Pheromone Signalling in the Asexual Fungus Fusarium oxysporum.Molecular plant pathology · 2026Article
- Antifungal and Antibiofilm Activities of 2-Aminobenzoic Acid Derivatives Against a Clinical OcularAntibiotics (Basel, Switzerland) · 2025Article
- Biofilm Formation in Clinical Isolates ofJournal of fungi (Basel, Switzerland) · 2024Article
- "Stop, Little Pot" as the Motto of Suppressive Management of Various Microbial Consortia.Microorganisms · 2024Review
- Strategic Single-Residue Substitution in the Antimicrobial Peptide Esc(1-21) Confers Activity againstACS infectious diseases · 2024Article
- Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.International journal of nanomedicine · 2024Article
- Silica nanoparticles containing nano-silver and chlorhexidine to suppressJournal of oral microbiology · 2024Article
- Unveiling the mechanism of action of acylated temporin L analogues against multidrug-resistantJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Effect of Escin Alone or in Combination with Antifungal Agents on ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Glycosylation and Lipidation Strategies: Approaches for Improving Antimicrobial Peptide Efficacy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Myxinidin-Derived Peptide against Biofilms Caused by Cystic Fibrosis Emerging Pathogens.International journal of molecular sciences · 2023Article
- VT-1161-A Tetrazole for Management of Mono- and Dual-Species Biofilms.Microorganisms · 2023Article
- An Overview of Supramolecular Platforms Boosting Drug Delivery.Bioinorganic chemistry and applications · 2023Review
- Synthetic Amphipathic β-Sheet Temporin-Derived Peptide with Dual Antibacterial and Anti-Inflammatory Activities.Antibiotics (Basel, Switzerland) · 2022Article
- Effect of Myrtenol and Its Synergistic Interactions with Antimicrobial Drugs in the Inhibition of Single and Mixed Biofilms ofMicroorganisms · 2022Article
- Mixed Fungal Biofilms: From Mycobiota to Devices, a New Challenge on Clinical Practice.Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During an infection, a single or multispecies biofilm can develop. Infections caused by non-dermatophyte molds, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.